VIDA Diagnostics, Inc., a Coralville, IA-based provider of precision pulmonary informatics has raised $5.1 million in Series B funding led by Chartline Capital Partners with participation from Rittenhouse Ventures, Next Level Ventures, Rural Vitality Fund II, Iowa Seed Fund, and Northern California Investment Fund. The latest round will be utilize to help commercialize VIDA’s pulmonary imaging software and associated Precision Services including hiring additional talent.
Founded in 2004, VIDA offers a unique lung informatics solution that is a combination of image analysis services (Precision Services) and software visualization and analytics (VIDA|vision). The solution spans both diagnostic and therapeutic planning applications. For suspected lung cancer patients, VIDA|vision provides interventional pulmonologists with airway mapping software to guide an optimal path for bronchoscopic biopsy. For severe emphysema patients, VIDA provides an array of advanced, clinically-validated measures to inform treatment selection to match the right patient to the right treatment, focusing on improving outcomes.
“Precision healthcare requires precision information,” said Susan A. Wood, Ph.D., President and CEO of VIDA in a statement. “Healthcare is moving to value quality of care over quantity of care. At VIDA, we are driven to improve treatment selection and therapy outcomes for pulmonary patients by equipping care teams with rich, evidence-based information they often lack today. This round B investment will help VIDA bring that information to the market, with the goal of improving quality of care.”
